SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...

Iptacopan is the first FDA-approved treatment for C3G, targeting the disease's underlying cause by inhibiting the alternative complement pathway. The phase 3 APPEAR-C3G study showed a 35.1% reduction ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...